MedTrace Logo

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma

NCT01436110 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 351

Last updated 2017-01-09

Study results available
· View outcomes & findings →

Summary

A randomised, double-blind, double-dummy, placebo controlled multi-centre study to evaluate the efficacy and safety of fluticasone furoate inhalation powder and fluticasone propionate inhalation powder in the treatment of asthma in adults and adolescents not currently treated with inhaled corticosteroids

Conditions

Interventions

DRUG

Fluticasone furoate 50mcg

Once daily inhalation powder via Novel Dry Powder Inhaler

DRUG

Fluticasone propionate 100mcg

Twice daily inhalation powder via DISKUS/ACCUHALER

DRUG

Placebo

Inhalation powder via Novel Dry Powder Inhaler and DISKUS?ACCUHALER

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States
  • Mexico
  • Netherlands
  • Peru
  • Poland
  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01436110 on ClinicalTrials.gov